Board Member
SAB Biotherapeutics, Inc. (SABS)Equibles does not estimate personal net worth.
Get an email with a short summary when SAB Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SABS alertsSamuel J. Reich is recorded as Board Member at SAB Biotherapeutics, Inc. (SABS) since January 1, 2020 and CEO at SAB Biotherapeutics, Inc. (SABS). The newest filing on record that lists Samuel J. Reich as CEO and Board Member at SAB Biotherapeutics, Inc. (SABS) is dated April 30, 2026. SAB Biotherapeutics, Inc. reported in an 8-K filed February 2, 2024 that Samuel J. Reich was appointed Chief Executive Officer, effective January 30, 2024. Samuel J. Reich has spoken on 1 earnings call and 2 other investor events across 1 company, most recently for SAB Biotherapeutics, Inc. on August 6, 2026. SAB Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at SAB Biotherapeutics, Inc. includes David Zaccardelli (Chairman and Board Member), Lucy To (CFO), Mark Conley (CFO) and 7 others.
“On January 30, 2024, Samuel J. Reich, age 49, the Executive Chairman of the Board of Directors (the "Board") of SAB Biotherapeutics, Inc. (the "Company"), was appointed Chief Executive Officer of the Company, effective immediately.”
“Good morning, and thank you to everyone joining us for our second quarter 2026 earnings call. I'm joined today by Lucy To, our Chief Financial Officer, who will review the second quarter financial update.”
“So, SAB Bio is a clinical stage biotech company. Our lead asset, SAB142, is a multi-specific T-cell engaging agent for autoimmune disease. It's currently in phase 2B, a pivotal study in newly diagnosed type 1 diabetes patients.”
“So our mission at SAB Bio is to transform what it means to get a type 1 diabetes diagnosis by developing a therapy to change the course of disease and not just manage the symptoms.”
2020-01-01–present
Last confirmed April 30, 2026
Start not stated–present
Last confirmed April 30, 2026
2020-01-01–2023-05-19
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO, Board Member
2020-01-01–present
